{
  "id": 11432028,
  "title": "Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome",
  "url": "https://urgent.news/2026/10/02/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T12:05:45.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome"
  },
  "original_language": "en",
  "account": null,
  "summary": "Teva Pharmaceuticals has unveiled new efficacy and safety data for ecopipam, an investigational selective D1 (dopamine) receptor antagonist intended for pediatric patients with Tourette syndrome, at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea. The data, presented at the conference from October 4–8, 2026, encompass a post hoc analysis of safety and efficacy during the initial eight weeks of treatment, long-term efficacy and safety from an ongoing open-label extension study, subgroup analyses, and preclinical receptor selectivity findings.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}